

Research Article

Unlocking the potential of Lion's Mane Mushroom (*Hericium erinaceus*)

Sabyasachi Banerjee

School of Agriculture, Lovely Professional University, Phagwara-144005 (Punjab), India

Shruti Gupta

School of Agriculture, Lovely Professional University, Phagwara-144005 (Punjab), India

Ritu Raj

School of Agriculture, Lovely Professional University, Phagwara-144005 (Punjab), India

Mudra Gupta

School of Agriculture, Lovely Professional University, Phagwara-144005 (Punjab), India

Sonam Kumari

School of Agriculture, Lovely Professional University, Phagwara-144005 (Punjab), India

Gurpreet Kaur*

Department of Plant Pathology, Lovely Professional University, Phagwara-144005 (Punjab), India

*Corresponding author. E-mail: gurpreetbchandel@gmail.com

Article Info

<https://doi.org/10.31018/jans.v16i1.5224>

Received: October 20, 2023

Revised: January 7, 2024

Accepted: January 18, 2024

How to Cite

Banerjee. S. *et al.* (2023). Unlocking the potential of Lion's Mane Mushroom (*Hericium erinaceus*). *Journal of Applied and Natural Science*, 16(1), 39 - 50. <https://doi.org/10.31018/jans.v16i1.5224>

Abstract

The Lion's Mane mushroom, botanically known as *Hericium erinaceus*, stands out as a unique and esteemed member of the fungal kingdom. This extraordinary mushroom not only possesses an alluring appearance but also holds a significant historical presence in diverse cultures, especially within the context of ancient herbal medicine practices. This fungus holds promising prospects in several domains. Its potential as a natural remedy for cognitive health is gaining attention. This mushroom has neuroprotective properties and could play a role in supporting brain function, which is particularly relevant in the present aging population where neurodegenerative conditions like Alzheimer's disease are a growing concern. Furthermore, Lion's Mane has been explored for its potential in addressing mood disorders. It is a rich source of bioactive compounds, including β -glucans, that can positively affect the immune system. The fungus produces bioactive compounds that can be used to treat various chronic diseases like obesity, high blood pressure, hepatic disorders, and cancer ; it also has other benefits like wound healing and improving the immune system. This review endeavours to elucidate the multifaceted potential of Lion's Mane mushroom within the domains of nutrition, health, and wellness. Through a comprehensive examination of its properties and benefits, the review explored how Lion's Mane mushrooms can be harnessed to enhance human well-being. By unlocking the secrets hidden within this remarkable fungus, the study provides insights that can empower individuals to incorporate Lion's Mane into their daily lives, fostering a healthier and more balanced lifestyle.

Keywords: Bioactive compound, Edible fungi, Lion's Mane mushroom, Medicinal mushroom

INTRODUCTION

Medicinal plants and herbs hold significant importance in the context of traditional treatments. Approximately 140,000 to 150,000 mushroom species have been recognized for producing diverse medicinal compounds and about 700 medicinal compounds have been identified from these species (Bacha *et al.*, 2018). Lion's Mane mushroom is among many medicinal mushrooms renowned for their potential health benefits and therapeutic properties. Referred to as fungi, these or-

ganisms encompass the visible fruiting body and the underlying mycelium, constituting a unique biological category. Humans have always fascinated by nature and their properties of mushrooms and gathered knowledge about their medicinal properties. Lion's Mane belongs to the category of higher fungi, also known as macro-fungi. Among the 14,000 identified species of higher fungi, 350 are recognized as edible and consumed by humans (Niego *et al.*, 2021). Its intriguing name was derived from its unique appearance, which resembles the cascading tendrils of a lion's

mane. Its long, fringed, snow-white spines instantly make it recognizable in its natural habitat. It is prevalent in the United Kingdom, Japan, Europe, East Asia, and the temperate latitudes of the southern hemisphere (David and Williams, 2023).

The fungus commonly thrives on mature trees with broad canopies, such as old pollards or well-established specimens, but it can occasionally produce fruiting bodies on younger trees that have been injured or damaged (Sokol *et al.*, 2015). In the natural environment, it reproduces via spores. These spores exhibit considerable resilience to diverse climatic conditions and can endure for a duration of up to seven years. It seems to thrive in warmth rather than intense heat, flourishing particularly in temperatures ranging from 25 to 30°C. While it can also develop in cooler conditions, such as 20°C, it does not thrive in freezing temperatures. Sporulation ceases when temperatures reach 31-33°C, elucidating its prevalence in Europe during late summer or autumn. It can prosper both in humid and acidic environments (Thongbai *et al.*, 2015; He *et al.*, 2017). However, it does not thrive in tropical or subtropical regions, and it shows a preference for moderate rather than high humidity levels (David and Williams, 2023)

COMMERCIAL CULTIVATION

The Lion's Mane mushroom is an uncommon species, and the unauthorized harvesting of its wild fruiting bodies in the United Kingdom is rigorously forbidden. This fungus was artificially cultivated for the very first time in China, under controlled environments using synthetic logs that are enclosed within polypropylene bags and bottles (Imtiaj *et al.*, 2008) This mushroom requires an optimal temperature range of 18-24 °C and 80-90 per cent relative humidity for the mycelial growth. Adequate fresh air circulation for about 5-8 hours is essential, and it flourishes best in light conditions ranging from 500 to 1000 lux (Bacha *et al.*, 2018).

Despite its nutritional value, it is highly regarded for its mild flavor and succulent texture. Even though wild

fruiting bodies are rare, it is very easy to cultivate this fungus using agricultural byproducts abundant in cellulose (Table 1). Lion's mane mushroom consists of various components such as carbohydrates (60.95 %), protein (42.5 %), ash (8.9 %), low fats (7.9 %), crude fiber (7.81 %) and amino acids (Bacha *et al.*, 2018).

Benefits of Lion's mane mushroom:

Lion's mane mushroom contains bioactive compounds such as hericerins, alkaloids, steroids, polysaccharides and erinacines (Table 2). Among these the terpenoid compounds like hericenones obtained from the fruiting body of the fungi and erinacines obtained from cultured media stimulate synthesis of Nerve growth factor (NGF).

Among these, the most significant results have been found in treating Parkinson's and Alzheimer disease. It also has antitumor, antidiabetic and anticancerous properties (Fig. 1).

Improve brain function

Li *et al.* (2020) conducted a study wherein for a period of 49 weeks Chinese nationals were given 350 mg capsules three times daily, each containing 5 mg/g of erinacine A, and the results showed improvements in various blood biomarkers, including calcium, hemoglobin, albumin, brain-derived neurotrophic factor, superoxide dismutase, and homocysteine. Moreover, participants who consumed capsules containing *Hericium erinaceus* mycelium also showed enhancements in alpha-ACT (α -ACT) and reductions in β -amyloid levels. These findings indicate improved cognitive abilities and greater levels of Neurocognitive benefits (social cognition, language, learning, memory, executive function and perceptual-motor skills). Martínez-Mármol *et al.* (2023) reported that Hericene-A functions by utilizing a unique signaling pathway that promotes overall neurotrophic effects, enhancing cognitive abilities. Kuo *et al.* (2016) reported that mycelium of *H. erinaceus* alleviate the damaging impact on neuronal cells within an animal model treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Kuo *et al.*, 2016). *H. erinaceus* can

Table 1. Cultivation of Lion's Mane mushroom using Agricultural Waste

Developmental Stages	Organs	Agricultural Products
Vegetative	Mycelia	Rice bran, wheat bran, barley bran, egg shell Chinese cabbage, soybean powder, Potato dextrose agar medium, yeast malt medium, oak saw dust medium Sunflower seed hulls Tofu whey
Reproductive	Fruiting Body	Agro wastes (rice straw, soybean dregs, sugarcane bagasse) Textile industry wastes (hemp, rye straw, flax shive, alder sawdust,) Artemisia capillaries

Source : Bacha *et al.*, (2018).

be used to treat various cognitive impairments (Mori *et al.*, 2009), Alzheimer disease (Tzeng *et al.*, 2016), Parkinson's disease (Kuo *et al.*, 2016), Ischemic stroke (Lee *et al.*, 2014), Presbycusis (Chan *et al.*, 2019).

Support digestive health

Peptic ulcers, encompassing gastric and duodenal ulcers, have posed a significant health concern for the global population (Xie *et al.*, 2022). The main factors contributing to peptic ulcer disease include persistent inflammation triggered by *Helicobacter pylori* infection and the consumption of nonsteroidal anti-inflammatory drug (NSAIDs) (Narayanan *et al.*, 2018) The gastric mucus barrier serves a vital function in protecting the stomach (Allen and Flemstrom, 2005; Jia *et al.*, 2023). When animals were pretreated with an aqueous extract of *H. erinaceus*, there was a notable enhancement in gastroprotection. This was evident as there was a significant increase in free mucus compared to animals with ulcers but without treatment. This mucus primarily consisted of mucin-type glycoprotein, identified using alcian blue dye. Alcian blue dye binds to substances with negative charges.

The mucus gel that adheres to the surface of the gastric mucosa acts as a shield, safeguarding the underlying epithelium from substances like acid pepsin and damaging agents such as ethanol and indomethacin (Devaraj *et al.*, 2011). However, it is important to note that according to Allen and Flemstrom (2005), the mucus lining the gastric wall plays a more crucial role in protecting the gastric mucosa against chemical or mechanical threats than the soluble mucus found within the stomach's lumen. This gastric wall mucus coating may contribute to the healing of damaged gastric epi-

thelium (Shih *et al.*, 2005; Hagen 2021). Therefore, the increased capacity of alcian blue binding suggests that the aqueous extract of *H. erinaceus* can activate the defensive system of the gastric mucus barrier.

Relieve depression and anxiety

Depression is a prevalent and severe neuropsychiatric condition, ranking among the top contributors to the worldwide burden of disease. While there are numerous antidepressant medications on the market, their effectiveness is often limited, and a significant number of them come with undesirable side effects. There are various hypotheses involved in depression about how it works. One of the hypothesis is monoamine hypothesis, which state that the symptoms and expressions of depression are linked with impairment of monoamine systems, that encompass serotonin, norepinephrine and potentially dopamine (Coppen 1967; Schildkraut 2006; Chong *et al.*, 2019). Reduced transmission of monoamine neurotransmitters can occur due to a range of factors, including deficits or malfunctions in monoamine precursor molecules, receptors, enzymes, and transporters, as well as issues related to monoamine synthesis (Fig. 2). Moreover, an increase in monoamine oxidase activity and reduced exocytosis can contribute to this deficiency.

Clinical observations conducted in vivo have supplied substantial evidence in favour of the monoamine hypothesis (Bunney and Davis 1965; Coppen 1967; Schildkraut 2006; Chong *et al.*, 2019). When animals displaying depressive-like symptoms were given *H. erinaceus* orally, it produced effects similar to those of conventional antidepressant medications. It is noted that *H. erinaceus* helps reinstate serotonin, norepineph-




Fig. 1. Benefits of Lion's mane mushrooms

Table 2. Bioactive compounds of *Hericum erinaceum* and their therapeutic potential.

List of compounds	Action	Medical use	References
Polysaccharides β-D-glucans	Anti-carcinogenic	Stomach and intestinal cancers (gastric, liver, colorectal), Leukemia	Sokol <i>et al.</i> , (2015); David and William (2023)
	Immune response modulation	For treating cancers	
	Gastrointestinal shielding	Chronic gastritis, ulcers	
	Bactericidal effect	Ailments caused by <i>Helicobacter pylori</i>	
	Reduction of Cholesterol and tri-glyceride levels	Hyperlipidaemia	
	Anti-hyperglycemic	Diabetes	
Polyphenols	Liver function support	Liver tissue injury	Sokol <i>et al.</i> , (2015); David and William (2023)
	Oxidative stress protection	Skin rejuvenation	
Hericenones A–B	Anti-thrombotic	Thrombosis, vascular diseases, stroke	Sokol <i>et al.</i> , (2015); David and William (2023)
	Cytolytic	Cancers	
Hericirine	Diminishing inflammatory signaling molecules and immune system messengers (cytokines)	Inflammatory ailments	Sokol <i>et al.</i> , (2015); David and William (2023)
Hericenones C–H, erinacines A–I	Neuro-restorative, Nerve cell preservation	Dementia, Alzheimer's and Parkinson's diseases, depression	Sokol <i>et al.</i> , (2015); David and William (2023)
Erinacine A	Heightened synthesis of neurotrophins, leading to elevated levels of nerve growth factor messenger RNA (NGF mRNA).	Neuroregenerative treatments for neurological disorders or injuries	Rupcic <i>et al.</i> , (2018)
Erinacine B	Augmented generation of neurotrophins, specifically an elevation in the production of nerve growth factor messenger RNA (mRNA).	Treatment of neurodegenerative disorders, nerve injuries, and conditions where enhanced neural regeneration is desired	Rupcic <i>et al.</i> , (2018)
Erinacine C	Mitigating neuroinflammation by decreasing the levels of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), and hindering the activation of NF-κB and the phosphorylation of IκBα.	Treatment of various neurological disorders	Wang <i>et al.</i> , (2019)
Erinacine P	Substantial promotion of the extension of neuronal projections (neurites).	Treatment of conditions involving nerve injuries, neurodegenerative diseases, or other disorders where the promotion of neural growth and connectivity is desirable	Zhang <i>et al.</i> , (2018)
Erinacine S	The promotion of neurite outgrowth in primary neurons from both the central nervous system (CNS) and peripheral nervous system (PNS) is significantly increased.	Promotes nerve regeneration and functional recovery in cases of injuries to both the CNS and PNS	Lin <i>et al.</i> , (2023)
Erinacine W,X,Y	Induced growth of neuronal projections	Repair and recovery of damaged nerves, which is particularly relevant in conditions involving nerve injuries or neurodegenerative diseases	Ma <i>et al.</i> , (2021)
Hericenone F	Diminished nitric oxide (NO) production resulting in an anti-inflammatory effect	Treatment of inflammatory conditions	Lee <i>et al.</i> , (2016)
Isohericerinol Corallocin A	A, Elevated the production of brain-derived neurotrophic factor (BDNF) protein.	Treatment of neurodegenerative disorders, mood disorders, and other conditions where neuronal health and plasticity are critical	Ryu <i>et al.</i> , (2021)

rine, and dopamine levels in these animals (Chiu *et al.*, 2018; Chong *et al.*, 2021). This fungus's fruiting bodies and mycelia consist of various bioactive compounds that can stimulate the production of several neurotrophic factors (Kawagishi *et al.*, 1992; Kawagishi *et al.*, 1994; Kawagishi *et al.*, 1996; Kushairi *et al.*, 2019). The majority of identified bioactive compounds responsible for producing antidepressant-like effects are primarily linked to their ability to stimulate NGF (Nerve Growth Factor) production (Mori *et al.*, 2008; Li *et al.*, 2018) and also nerve cells (Wong *et al.*, 2007; David and Williams 2023). In the context of *H. erinaceus*, the bioactive compounds responsible for affecting NGF release are mainly hericenones and erinacines. Due to their small molecular size they can easily penetrate the blood-brain barrier (Huang *et al.*, 2021). Nagano *et al.* (2010) conducted an experiment to study the effects of *H. erinaceus* on depression, menopause, sleep quality and indefinite complaints, wherein 30 females were randomly given *H. erinaceus* (HE) cookies or placebo cookies for 4 weeks. It was found that each of the Center for Epidemiologic Studies Depression Scale and the Indefinite Complaints Index scores after the HE intake was significantly lower than before. Hence, it was proved that HE intake can reduce anxiety and depression but the mode of action in this case differed from the NGF-enhancing action of *H. erinaceus*. Ryu *et al.* (2018) carried out a study to evaluate the antidepressant and anxiolytic potential of ethanolic extract derived

from *H. erinaceus* in adult mice and found that mice fed with extract of *H. erinaceus* showed significant changes in antidepressant effects.

Boost immune health

Lion's Mane mushroom is recognized for its abundance of beta-glucans, especially beta 1-3, 1-6 glucan, among the various mushroom varieties rich in this compound (Kawagishi *et al.*, 1992), it also contains erinacines (Kawagishi *et al.*, 1992; Kawagishi *et al.*, 1994; Nagai *et al.*, 2006), Hericenones (Mori *et al.*, 2009), dilinoleoyl-phosphatidylethanolamine, DLPE (Kawagishi 2006), terpene compounds (Kenmoku *et al.*, 2001), protein vitamins (Wu *et al.*, 2012) amino acids (Li *et al.*, 2014). Mushroom-derived β -glucans are well-known for their potent immunomodulatory properties, surpassing other types in terms of their ability to affect immune and inflammatory responses (Han *et al.*, 2020; Ikewaki *et al.*, 2021). Immunomodulation involves the capacity to correct aberrant immune functions, which can entail bolstering weakened or suppressed aspects or normalizing hyperactive or excessive functions (Jesenak *et al.*, 2014)

Because of their versatile mechanism of action, β -glucans are recognized as biological response modifiers. They alter the epigenetic profile of innate immune cells, leading to an enhanced immune response. Additionally, they serve as pathogen-associated molecular patterns, binding to specific receptors for pathogen




Fig. 2. Monoamine hypothesis of depression

recognition, thereby triggering innate and adaptive immune reactions (Han *et al.*, 2020; Ikwaki *et al.*, 2021). These β -glucans can additionally boost the performance of macrophages and neutrophils, bolster the capabilities of natural killer (NK) cells, affect the generation of cytokines and chemokines, and oversee the control of antibody production, among a myriad of other roles. Therefore, it can be concluded that Hericenone can increase the immune health. *H. erinaceus* fruiting body contains various compounds that show hemagglutination (Gong *et al.*, 2004). This fungus also shows anti microbial properties (Yim *et al.*, 2007; Chong *et al.*, 2019), immunomodulatory (Kim *et al.*, 2012; Zhao *et al.*, 2020), anti-aging (Zhang *et al.*, 2012; Tripodi *et al.*, 2022), anti-oxidant properties (Malinowska *et al.*, 2009; Hsu *et al.*, 2023).

Prevent cancer

Erinacine-A potentially triggers a series of programmed cell death events in TSGH 9201 cells (Mori *et al.*, 2009) through the activation of the FAK/AKT/p70S6K/PAK1 pathway and the increased expression of proteins 1433S and MTUS2. This offers a novel explanation for how this compound exerts its anti-cancer effects on human gastric cancer cells (Li *et al.*, 2014). This potent anti-tumor effect of Erinacin-A has been further validated by a study, which not only replicated these findings *in vitro* using two human colon cancer cell lines (DLD-1 and HCT-116) but also confirmed its efficacy in an *in vivo* mouse model. This subsequent research provided additional insights into the mechanisms underlying its strong anti-tumor properties and also increased NK

cells (Figure-3) (Lee *et al.*, 2019).

Utilizing the body's innate immune system to target cancerous cells, NK cell-based immunotherapy represents an innovative frontier in cancer treatment (Cheent and Khakoo 2009; Shin *et al.*, 2020) This innovative therapy capitalizes on the unique abilities of NK cells, which are a type of white blood cell with a natural propensity to target and destroy cancerous cell (Cheng *et al.*, 2013; Liu *et al.*, 2021). NK cell-based immunotherapy holds great promise for various cancers, including leukemia, lymphoma, and solid tumors. It offers a targeted and less toxic alternative to traditional cancer treatments like chemotherapy and radiation therapy. However, challenges remain, such as optimizing NK cell expansion, persistence and overcoming the immunosuppressive tumor microenvironment. Ongoing research and clinical trials aim to refine this approach further and improve its efficacy to fight against malignant cells.

The polysaccharides present in *H. erinaceus* have the capacity to modulate pro-inflammatory cytokines, trigger immune responses mediated by macrophages, and stimulate the maturation of dendritic cells (Sheu *et al.*, 2013). Reducing cancer risk is possible through a well-rounded diet and making appropriate lifestyle decisions. Laboratory studies indicate that Lion's Mane contains polysaccharides and aromatic compounds with anti-cancer properties. Researchers have identified multiple mechanisms through which Lion's Mane extract can inhibit the proliferation of diverse cancer cells, including those associated with lung and breast cancer.




Fig. 3. Natural killer cell based therapy for malignant cells

Investigations are ongoing to understand its potential role as a supplementary treatment in cancer care. (Atay *et al.*, 2021). The presence of polysaccharides, hericirine, polyphenols, and various other compounds in Lion's Mane contributes to the inhibition of inflammation, provides antioxidant benefits, and regulates immune responses. Consequently, consistent consumption may contribute to the reinforcement of the immune system (Meena *et al.*, 2020).

Manage diabetes

In the year 2000, diabetes was determined to have a worldwide prevalence of 2.8 per cent among people of all age groups, and it is anticipated to increase to 4.4 per cent by the year 2030 (Wild *et al.*, 2004; Kaveeshwar *et al.*, 2014). In diabetes mellitus, persistent high levels of blood sugar lead to a range of biochemical irregularities (Giugliano *et al.*, 1996; Rajasekaran *et al.*, 2005), Oxidative stress plays a significant role in the development of diabetes (Nishikawa *et al.*, 2000; Forbes *et al.*, 2008; Giacco and Brownlee, 2010). Clinical investigations have shown that strict management of hyperglycemia can lower the risk or slow down the progression of diabetes. Nevertheless, with the existing medications for lowering blood sugar levels, achieving and sustaining precise glycemic control in diabetic individuals can be challenging (Nathan *et al.*, 1993; Ohkubo *et al.*, 1995; Dronavalli *et al.*, 2008). The substantial antioxidant capabilities and presence of bioactive compounds in *Hericium erinaceus* make it a valuable resource for addressing metabolic disorders, particularly in the context of diabetes treatment (Chaiyasut *et al.*, 2017). Exo-biopolymer derived from *H. erinaceus* mycelial culture has beneficial impact on lowering lipid levels in rats with diet-induced hyperlipidemia (Han *et al.*, 2013) as well as lowering the glycemic index in animals (Wang *et al.*, 2005). All these studies concludes that lion's mane can reduce the lipid accumulation in the body and also reduces the glycemic index.

The hypoglycemic and antihyperlipidemic effects of the aqueous extract from *H. erinaceus* have been documented in experimental rat models. The addition of *H. erinaceus* extract (at doses of 100–200 mg/kg body weight) resulted in enhanced serum insulin levels and decreased glucose levels in diabetic rats induced by streptozotocin. The study also indicated that supplementation with *H. erinaceus* aqueous extract demonstrated antihyperlipidemic properties and enhanced the activity of free radical scavenging enzymes (Liang *et al.*, 2013). Wu and Xu (2015) documented the *in vitro* antidiabetic properties of *H. erinaceus*, highlighting that the suppression of α -glycosidase and aldose reductase activity occurred in a dose-dependent manner. Zhang *et al.* (2015) observed that the ethanolic extract derived from *H. erinaceus* demonstrated anti-neuropathic pain effects in a diabetic neuropathic Wistar rat model

induced by alloxan. Supplementation with approximately 40 mg of the ethanolic extract per kilogram of body weight led to a reduction in neuropathic pain, increased inhibition of lipid peroxidation, and enhanced activities of antioxidant enzymes such as lactate dehydrogenase, glutathione peroxidase, glutathione reductase, catalase, Na⁺ K⁺ ATPase, and glutathione S transferase in the experimental rats. The findings suggested that the improvement in the host's antioxidant system by *H. erinaceus* extract could be accountable for the alleviated diabetic neuropathy.

Reduce heart disease risk

Atherosclerosis, which is a multifaceted pathological progression, accounts for over 50 per cent of fatalities in industrialized nations (Murray *et al.*, 1997). The primary factor implicated in the initiation of atherosclerosis is commonly identified as the oxidative modification of low-density lipoprotein (LDL). Atherosclerosis is the major reason that ultimately result in cardiovascular diseases (CVD) and strokes (Murray *et al.*, 1997; Libby, 2002; Roger *et al.*, 2012). The factors governing the oxidation of LDL lay the groundwork for the harmful progression of atherosclerosis (Li and Mehta, 2005; Yoshida and Kisugi 2010; Rahman *et al.*, 2014). Oxidized LDL is readily taken up by macrophages. Mushrooms have naturally low fat content and do not contribute to elevated cholesterol levels. Moreover, specific mushrooms, such as Lion's Mane, contain compounds that inhibit lipid oxidation and demonstrate an antihyperlipidemic effect. Consequently, Lion's Mane is recognized as beneficial for cardiovascular health (Jang *et al.*, 2017). *Hericium erinaceus* extracts possess inhibitory effect on HMG CO-A reductase activity and *in vitro* LDL oxidation (Rahman *et al.* 2014). Mushrooms have been recognized for their capacity to inhibit both cholesterol production (Rahman *et al.*, 2014) and absorption (Bobek *et al.*, 1994; Berger *et al.*, 2004) as well as promote the excretion of cholesterol through feces (Yang *et al.*, 2013). Additionally, the dietary fibers found in mushrooms contribute to their effectiveness as agents for reducing lipid levels (Cheng *et al.*, 2002; Ganesan and Xu 2018).

Limited evidence from experimental research suggests that incorporating mushrooms into the diet has a positive impact on serum/plasma triglycerides and High-sensitivity C-reactive protein (hs-CRP) levels. Increased mushroom consumption is associated with reduced levels of blood triglycerides and hs-CRP, which are indicators of cardiometabolic health. (Uffelmann *et al.*, 2023). L-ergothioneine is an amino acid obtained from the diet, known for its antioxidant and anti-inflammatory characteristics, which are linked to the onset of various degenerative and chronic conditions, including several cardiometabolic diseases (CMD) (Nguyen *et al.*, 2013). Notably, animals and

higher plants do not produce L-ergothioneine; instead, it is biosynthesized by mushrooms, cyanobacteria, and certain soil bacteria. While L-ergothioneine is present in low levels in various foods, mushrooms stand out as the most significant dietary sources (Kalaras et al., 2020).

Conclusion

Lion's Mane products, such as supplements and functional foods, are expected to become more popular. Moreover, Lion's Mane's unique culinary qualities, resembling the taste and texture of seafood, make it a sought-after ingredient for plant-based and vegetarian diets. Its adaptability in various recipes and dishes adds to its appeal in the culinary world. In the context of agriculture and sustainability, Lion's Mane cultivation is relatively eco-friendly, requiring minimal resources and space. As the demand for sustainable and locally sourced food grows, the cultivation of this mushroom could play a role in meeting these preferences. In conclusion, Lion's Mane mushroom is poised for a bright future, driven by its potential in brain health, mental well-being, nutrition, culinary applications, and sustainability. Continued research and innovation in harnessing its benefits may lead to even more exciting developments in the future.

Conflict of interest

The authors declare that there is no competing interest.

REFERENCES

- Allen, A. & Flemstrom, G. (2005). Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. *J. Physiol. Cell Physiol*, 288(1), C1-19. doi: 10.1152/ajpcell.00102.2004
- Atay, S., Ak, H., Kalmis, E., Kayalar, H. & Aydin, H. (2020). Transcriptome Wide Analysis Reveals the Molecular Mechanism of Tumoricidal Effects of Lion's Mane Medicinal Mushroom, *Hericium erinaceus* (Agaricomycetes) on MCF-7 Breast Cancer Cells. *Int. J. Med. Mushrooms*, 23(1). doi: 10.1615/IntJMedMushrooms.2020037448
- Bacha, S. A. S., Ali, S., Li, Y., Rehman, H. U., Farooq, S., Mushtaq, A. & Wahocho, S. A. (2018). Lion's mane mushroom; new addition to food and natural bounty for human wellness: A review. *Int. J. Biosci*, 396-402. doi:10.12692/ijb/13.4
- Berger, A., Rein, D., Kratky, E., Monnard, I., Hajjaj, H., Meirim, I., Piguet, C., Hauser, J., Mace, K. & Niederberger, P. (2004). Cholesterol-lowering properties of *Ganoderma lucidum* in vitro, ex vivo, and in hamsters and minipigs. *Lipids Health Dis*, 18,32-34. doi: 10.1186/1476-511X-3-2
- Bobek, P., Ozdin, L. & Kuniak, L. (1994). Mechanism of hypocholesterolemic effect of oyster mushroom (*Pleurotus ostreatus*) in rats: reduction of cholesterol absorption and increase of plasma cholesterol removal. *Zeitschrift fur Ernahrungswissenschaft*, 33(1), 44-50. <https://doi.org/10.1007/bf01610577>
- Bunney, W. E. Jr. & Davis, J. M. (1965). Norepinephrine in depressive reactions. A review. *Arch Gen Psychiatry*, 13(6), 483-94. doi: 10.1001/archpsyc.1965.01730060001001
- Chaiyasut, C. & Sivamaruthi, B. S. (2017). Anti-hyperglycemic property of *Hericium erinaceus* – A mini review. *Asian Pac. J. Trop. Biomed*, 7(11): 1036-1040. <https://doi.org/10.1016/j.apjtb.2017.09.024>
- Chan, Y. C., Chen, C. C., Lee, L. Y. & Chen, W. P. (2019). Active Substances for Preventing Hearing Deterioration, the Composition Containing the Active Substances, and the Preparation Method Thereof. 10,405,504. U.S. Patent.
- Cheent, K. & Khakoo, S.I. (2009). Natural killer cells: integrating diversity with function. *Immunology*, 126, 449-457.
- Cheng, H. H., Hou, W. C. & Lu, M. L. (2002). Interactions of lipid metabolism and intestinal physiology with *Tremella fuciformis* Berk edible mushroom in rats fed a high-cholesterol diet with or without Nebacitin. *J. Agric. Food Chem*. 50(25),7438-43. doi: 10.1021/jf020648q
- Cheng, M., Chen, Y. & Xiao, W. (2013). NK cell-based immunotherapy for malignant diseases. *Cell Mol. Immunol*. 10, 230-252. <https://doi.org/10.1038/cmi.2013.10>
- Chiu, C. H., Chyau, C. C., Chen, C. C., Lee, L. Y., Chen, W. P., Liu, J. L., Lin, W. H. & Mong, M. C. (2018). Erinacine A-enriched *Hericium erinaceus* mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3 β signaling in mice. *Int. J. Mol. Sci*, 19(2), 341. doi: 10.3390/ijms19020341
- Chong, P. S., Fung, M. L., Wong, K. H. & Lim, L. W. (2019). Therapeutic Potential of *Hericium erinaceus* for Depressive Disorder. *Int. J. Mol. Sci*. 21(1):163. doi: 10.3390/ijms21010163
- Chong, P. S., Poon, C. H., Roy, J., Tsui, K. C., Lew, S. Y., Phang, M. W. L., Tan, R. J. Y., Cheng, P. G., Fung, M. L., Wong, K. H. & Lim, L. W. (2021). Neurogenesis-dependent antidepressant-like activity of *Hericium erinaceus* in an animal model of depression. *Chin Med*. 16(1):132. doi: 10.1186/s13020-021-00546-8
- Coppen, A. (1967). The biochemistry of affective disorders. *Br. J. Psychiatry*, 113, 1237-1264. doi: 10.1192/bjp.113.504.1237
- David, G., & Williams, J. (2023). Lion's Mane Mushroom-From Culinary to Medicine. *Ann. Med*, 1(2). <https://doi.org/10.59652/aim.v1i2.55Niego2>
- Devaraj, V. C., Gopala, K. B., Viswanatha, G. L., Prasad, V. S. & Babu, S. N. V. (2011). Protective effect of leaves of *Raphinus sativus* Linn on experimentally induced gastric ulcers in rats. *Saudi Pharmaceutical Journal*, 19,171-176. doi:10.1016/j.jsps.2011.03.003
- Dronavalli, S., Duka, I. & Bakris, G. L. (2008). The pathogenesis of diabetic nephropathy. *Nat Clin Pract Endocrinol Metab*, 4(8), 444-452.
- Forbes, J. M., Coughlan, M. T. & Cooper, M. E. (2008). Oxidative stress as a major culprit in kidney disease in diabetes. *Diabetes*, 57(6), 1446-1454. doi: 10.2337/db08-0057
- Ganesan, K. & Xu, B. (2018). Anti-Obesity Effects of Medicinal and Edible Mushrooms. *Molecules*, 23(11), 2880. doi: 10.3390/molecules23112880

21. Giacco, F. & Brownlee, M. (2010). Oxidative stress and diabetic complications. *Circ. Res.* 107(9),1058–1070. doi: 10.1161/CIRCRESAHA.110.223545
22. Giugliano, D., Ceriello, A. & Paolisso, G. (1996). Oxidative stress and diabetic vascular complications. *Diabetes Care*, 19(3),257–267. doi: 10.2337/diacare.19.3.257
23. Gong, M., An, J., Lu, H. Z., Wu, C. F., Li, Y. J., Cheng, J. Q. & Bao, J. K. (2004). Effects of denaturation and amino acid modification on fluorescence spectrum and hemagglutinating activity of *Hericum erinaceum* Lectin. *Acta Biochim. Biophys. Sin.*, 36(5), 343–350. doi: 10.1093/abbs/36.5.343
24. Hagen, S. J. (2021). Mucosal defense: gastroduodenal injury and repair mechanisms. *Curr. Opin. Gastroenterol*, 37,609-614. doi: 10.1097/MOG.0000000000000775
25. Han, B., Baruah, K., Cox, E., Vanrompay, D. & Bossier, P. (2020). Structure-functional activity relationship of β -glucans from the perspective of immunomodulation: A mini-review. *Front. Immunol*, 11,658. doi: 10.3389/fimmu.2020.00658
26. Han, Z. H., Ye, J. M. & Wang, G. F. (2013). Evaluation of in vivo antioxidant activity of *Hericum erinaceus* polysaccharides. *Int. J. Biol. Macromol*, 52,66-71. doi: 10.1016/j.ijbiomac.2012.09.009
27. He, X., Wang, X., Fang, J., Chang, Y., Ning, N., Guo, H., Huang, L., Huang, X. & Zhao, Z. (2017). Structures, biological activities, and industrial applications of the polysaccharides from *Hericum erinaceus* (Lion's Mane) mushroom: A review. *Int. J. Biol. Macromol.*, 97, 228-237. doi: 10.1016/j.ijbiomac.2017.01.040
28. Hsu, C. H., Liao, E. C., Chiang, W. C. & Wang, K. L. (2023). Antioxidative Activities of Micronized Solid-State Cultivated *Hericum erinaceus* Rich in Erinacine A against MPTP-Induced Damages. *Molecules*, 28(8):3386. doi: 10.3390/molecules28083386
29. Huang, H.T., Ho, C. H., Sung, H. Y., Lee, L. Y., Chen, W. P., Chen, Y. W., Chin, C. C., Yang, C. H. & Tzeng, S. F. (2021). *Hericum erinaceus* mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein. *Erratum in: Sci Rep*,11(1), 9063. <https://doi.org/10.1038/s41598-021-85972-2>
30. Ikewaki, N., Iwasaki, M., Kurosawa, G., Rao, K. S., Lakey-Beitia, J., Preethy, S. & Abraham, S. J. (2021). β -glucans: Wide-spectrum immune-balancing food-supplement-based enteric (β -WIFE) vaccine adjuvant approach to COVID-19. *Hum. Vaccines. Immunother*, 17, 2808–2813. doi: 10.1080/21645515.2021.1880210
31. Imtiaj, A., Jayasinghe, C., Lee, G. W., Shim, M. J., Rho, H. S., Lee, H. S., Hur, H., Lee, M. W., Lee, U. Y. & Lee, T. S. (2008). Vegetative Growth of Four Strains of *Hericum erinaceus* Collected from Different Habitats. *Mycobiology*, 36(2), 88–92. doi: 10.4489/MYCO.2008.36.2.088
32. Jang, H. S. & Yoon, K. N. (2017). The Antihyperlipidemic Effect of Lion's Mane Mushroom (*Hericum erinaceus*) in Hyperlipidemic Rats Induced by High Fat and Cholesterol Diet. *Korean J. Clin. Lab. Sci*, 49:263–270. doi:10.15324/kjcls.2017.49.3.263
33. Jesenak, M., Hrubisko, M., Majtan, J., Rennerova, Z. & Banovcin, P. (2014). Anti-allergic effect of pleuran (β -glucan from *Pleurotus ostreatus*) in children with recurrent respiratory tract infections. *Phytother. Res.* 28, 471–474. doi: 10.1002/ptr.5020
34. Jia, X., He, Y., Li, L. & Xu, D. (2023). Pharmacological targeting of gastric mucosal barrier with traditional Chinese medications for repairing gastric mucosal injury. *Front. Pharmacol*, 14,109-1530. doi: 10.3389/fphar.2023.1091530
35. Kalaras, M. D., Richie, J. P., Calcagnotto, A. & Beelman, R. B. (2017). Mushrooms: A rich source of the antioxidants ergothioneine and glutathione. *Food Chem*, 233:429-433. doi:10.1016/j.foodchem.2017.04.109
36. Kaveeshwar, S. A. & Cornwall, J. (2014). The current state of diabetes mellitus in India. *Australas Med. J*, 7 (1):45-8. doi: 10.4066/AMJ.2013.1979
37. Kawagishi, H., Ando, M., Sakamoto, H., Yoshida, S., Ojima, F., Ishiguro, Y., Ukai, N. & Furukawa, S. (1991). Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom *Hericum erinaceum*. *Tetrahedron Lett*, 32, 4561-4564. doi: 10.1016/0040-4039(91)80039-9
38. Kawagishi, H., Ando, M., Shinba, K., Sakamoto, H., Yoshida, S., Ojima, F., Ishiguro, Y., Ukai, N. & Furukawa, S. (1992). Chromans, hericenones F, G and H from the mushroom *Hericum erinaceum*. *Phytochemistry*, 32,175-178. doi: 10.1016/0031-9422(92)80127-Z
39. Kawagishi, H., Mori, H., Uno, A., Kimura, A. & Chiba, S. (1994). A sialic acid-binding lectin from the mushroom *Hericum erinaceum*. *FEBS Lett*, 340(1-2),56–58. doi: 10.1016/0014-5793(94)80172-X
40. Kawagishi, H., Murakami, H., Sakai, S. & Inoue, S. (2006). Carnitine-esters from the mushroom *Suillus laricinus*. *Phytochemistry*, 67(24),2676–2680. doi: 10.1016/j.phytochem.2006.09.014
41. Kawagishi, H., Shimada, A., Hosokawa, S., Mori, H., Sakamoto, H., Ishiguro, Y., Sakemi, S., Bordner, J., Kojima, N. & Furukawa, S. (1996). Erinacines E, F, and G, stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of *Hericum erinaceum*. *Tetrahedron Lett*, 37, 7399-7402. doi: 10.1016/0040-4039(96)01687-5
42. Kawagishi, H., Shimada, A., Shirai, R., Okamoto, K., Ojima, F., Sakamoto, H., Ishiguro, Y. & Furukawa, S. (1994). Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of *Hericum erinaceum*. *Tetrahedron Lett*, 35,1569-1572. doi: 10.1016/S0040-4039(00)76760-8
43. Kawagishi, H., Shirai, R., Sakamoto, H. S., Ojima, F. & Ishiguro, Y. (1992). Erinapyrone-a and Erinapyrone-B from the Cultured Mycelia of *Hericum-Erinaceum*. *Chemistry Letters*, 12,2475–2476. doi:10.1246/cl.1992.2475
44. Kenmoku, H., Oozone, T., Sugai, T. & Sassa, T. (2001). Mass production of pure gibberellin A1 by *Phaeosphaeria* sp. L487 and the fungal preparation of [¹³C]gibberellin A1. *Biosci. Biotechnol. Biochem*, 65(9), 2095–2097. doi: 10.1271/bbb.65.2095
45. Kim, S. P., Moon, E., Nam, S. H. & Friedman, M. (2012). *Hericum erinaceus* mushroom extracts protect infected mice against *Salmonella* Typhimurium-Induced liver damage and mortality by stimulation of innate immune cells. *J. Agric. Food Chem*, 60(22), 5590–5596. doi: 10.1021/jf300897w
46. Kuo, H. C., Lu, C. C., Shen, C. H., Tung, S. Y., Hsieh, M. C., Lee, K. C., Lee, L. Y., Chen, C. C., Teng, C. C., Huang, W. S., Chen, T. C. & Lee, K. F. (2016). *Hericum*

- erinaceus* mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. *J. Transl. Med.* 14,78. doi: 10.1186/s12967-016-0831-y
47. Kushairi, N., Phan, C. W., Sabaratnam, V., David, P. & Naidu, M. (2019). Lion's Mane Mushroom, *Hericium erinaceus* (Bull.: Fr.) Pers. Suppresses H₂O₂-Induced Oxidative Damage and LPS-Induced Inflammation in HT22 Hippocampal Neurons and BV2 Microglia. *Antioxidants (Basel)*. 8(8):261. doi: 10.3390/antiox8080261
 48. Lee, D. G., Kang, H. W., Park, C. G., Ahn, Y.S. & Shin, Y. (2016). Isolation and identification of phytochemicals and biological activities of *Hericium erinaceus* and their contents in *Hericium* strains using HPLC/UV analysis. *J. Ethnopharmacol*, 184, 219–225. doi:10.1016/j.jep.2016.02.038
 49. Lee, K. F., Chen, J. H., Teng, C. C., Shen, C. H., Hsieh, M. C., Lu, C. C., Lee, K. C., Lee, L. Y., Chen, W. P., Chen, C. C., Huang, W. S. & Kuo, H. C. (2014). Protective effects of *Hericium erinaceus* mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death via the inhibition of iNOS/p38 MAPK and nitrotyrosine. *Int. J. Mol. Sci.* 15(9), 15073-89. doi: 10.3390/ijms150915073
 50. Lee, K., Lee, K. F., Tung, S., Huang, W., Lee, L., Chen, W., Chen, C., Teng, C., Shen, C. & Hsieh, M. (2019). Induction apoptosis of erinacine A in human colorectal cancer cells involving the expression of TNFR, Fas, and Fas ligand via the JNK/p300/p50 signaling pathway with histone acetylation. *Front. Pharmacol.* 10,1174. doi: 10.3389/fphar.2019.01174
 51. Li, D. & Mehta, J. L. (2005). Oxidized LDL, a critical factor in atherogenesis. *Cardiovascular Research*, 68(3),353–354. <https://doi.org/10.3390/ijms20102474>
 52. Li, G., Yu, K., Li, F., Xu, K., Li, J., He, S., Cao, S. & Tan, G. (2014). Anticancer potential of *Hericium erinaceus* extracts against human gastrointestinal cancers. *J. Ethnopharmacol*, 153(2), 521–530. doi: 10.1016/j.jep.2014.03.003
 53. Li, I. C., Chang, H. H., Lin, C. H., Chen, W. P., Lu, T. H., Lee, L. Y., Chen, Y. W., Chen, Y. P., Chen, C. C. & Lin, D. P. C. (2020). Prevention of Early Alzheimer's Disease by Erinacine A-Enriched *Hericium erinaceus* Mycelia Pilot Double-Blind Placebo-Controlled Study. *Front Aging Neurosci*, 12:155. doi: 10.3389/fnagi.2020.00155
 54. Li, I. C., Chen, Y. L., Lee, L. Y., Chen, W. P., Tsai, Y. T., Chen, C. C. & Chen, C. S. (2014). Evaluation of the toxicological safety of erinacine A-enriched *Hericium erinaceus* in a 28-day oral feeding study in Sprague-Dawley rats. *Food Chem. Toxicol*, 70,61-7.
 55. Li, I. C., Lee, L. Y., Tzeng, T. T., Chen, W. P., Chen, Y. P., Shiao, Y. J. & Chen, C.C. (2018). Neurohealth Properties of *Hericium erinaceus* Mycelia Enriched with Erinacines. *Behav Neurol*, 2018:5802634. doi: 10.1155/2018/5802634
 56. Liang, B., Guo, Z., Xie, F. & Zhao, A. (2013). Antihyperglycemic and antihyperlipidemic activities of aqueous extract of *Hericium erinaceus* in experimental diabetic rats. *BMC Complement Altern Med*, 13: 253. <https://doi.org/10.1186/1472-6882-13-253>
 57. Libby, P. (2002). Inflammation in atherosclerosis. *Nature*, 26,420 (6917), 868-74. doi: 10.1038/nature01323
 58. Lin, C. Y., Chen, Y. J., Hsu, C. H., Lin, Y. H., Chen, P. T., Kuo, T. H., Ho, C. T., Chen, H. H., Huang, S. J. & Chiu, H. C. (2023). Erinacine S from *Hericium erinaceus* mycelium promotes neuronal regeneration by inducing neurosteroids accumulation. *J. Food Drug Anal*, 31, 32–54. doi:10.38212/2224-6614.3446
 59. Liu, S., Galat, V. & Galat, Y. (2021). NK cell-based cancer immunotherapy: from basic biology to clinical development. *J. Hematol. Onco*, 14(7). <https://doi.org/10.1186/s13045-020-01014-w>
 60. Ma, K., Zhang, Y., Guo, C., Yang, Y., Han, J., Yu, B., Yin, W. & Liu, H. (2021). Reconstitution of biosynthetic pathway for mushroom-derived cyathane diterpenes in yeast and generation of new "non-natural" analogues. *Acta Pharm. Sin. B*, 11, 2945–2956. <https://doi.org/10.1016/j.apsb.2021.04.014>
 61. Malinowska, E., Krzyczkowski, W., Lapienis, G. & Herold, F. (2009). Improved simultaneous production of mycelial biomass and polysaccharides by submerged culture of *Hericium erinaceum*: optimization using a central composite rotatable design (CCRD). *J. Ind. Microbiol*, 36 (12),1513–1527.
 62. Martínez-Mármol, R., Chai, Y., Conroy, J. N., Khan, Z., Hong, S. M., Kim, S. B., Gormal, R. S., Lee, D. H., Lee, J. K., Coulson, E. J., Lee, M. K., Kim, S. Y. & Meunier, F. A. (2023). Hericerin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory. *J. Neurochem*,165, 791–808. <https://doi.org/10.1111/jnc.15767>
 63. Meena, B., Sivakumar, V. & Praneetha, S. (2020). Prospects of biodiversity and distribution of mushroom fungi in India. *GSC Biol. Pharm. Sci*, 13(1), 078–085. <https://doi.org/10.30574/gscbps.2020.13.1.0329>
 64. Mori, K., Inatomi, S., Ouchi, K., Azumi, Y. & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (*Hericium erinaceus*) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. *Phytother Res*, 23(3), 367-372. doi: 10.1002/ptr.2634.
 65. Mori, K., Obara, Y., Hirota, M., Azumi, Y., Kinugasa, S., Inatomi, S. & Nakahata, N. (2008). Nerve growth factor-inducing activity of *Hericium erinaceus* in 1321N1 human astrocytoma cells. *Biological and Pharmaceutical Bulletin*, 31,1727-1732. doi: <https://doi.org/10.1248/bpb.31.1727>
 66. Murray, C. J. & Lopez, A. D. (1997). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet*, 349(9063), 1436-42. doi: 10.1016/S0140-6736(96)07495-8
 67. Nagai, K., Chiba, A., Nishino, T., Kubota, T. & Kawagishi, H. (2006). Dilinoleoyl-phosphatidylethanolamine from *Hericium erinaceum* protects against ER stress-dependent Neuro2a cell death via protein kinase C pathway. *J. Nutr. Biochem*, 17(8), 525–530. doi: 10.1016/j.jnutbio.2005.09.007
 68. Nagano, M., Shimizu, K., Kondo, R., Hayashi, C., Sato, D., Kitagawa, K. & Ohnuki, K. (2010). Reduction of depression and anxiety by 4 weeks *Hericium erinaceus* intake. *Biomed Res*, 4,231-7. doi: 10.2220/biomedres.31.231
 69. Narayanan, M., Reddy, K. M. & Marsicano, E. (2018). Peptic Ulcer Disease and *Helicobacter pylori* infection. *Med*. 115(3), 219-224.
 70. Nathan, D. M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L. & Siebert, C. (1993). The effect of intensive treatment of diabetes on the development and

- progression of long-term complications in insulin-dependent diabetes mellitus. *N. Engl. J. Med.* 329(14), 977-86. doi: 10.1056/NEJM199309303291401
71. Nguyen, T. H., Nagasaka, R. & Ohshima, T. (2013). The Natural Antioxidant Ergothioneine: Resources, Chemical Characterization, and Applications; Logan, A., Nienaber, U., Pan, X., Eds., AOCs Press: Urbana, IL, USA,; ISBN 978-0-9830791-6-3.
72. Niego, A. G., Rapior, S., Thongklang, N., Raspe, O., Jaidee, W., Lumyong, S., & Hyde, K. D. (2021). Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value. *J. Fungi (Basel)*, 7(5), 397. <https://doi.org/10.3390/jof7050397>
73. Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J. & Hammes, H. P. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*, 404(6779),787–790. doi: 10.1038/35008121
74. Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N. & Shichiri, M. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res. Clin. Pract.* 28(2), 103–117. doi: 10.1016/0168-8227(95)01064-K
75. Rahman, M. A., Abdullah, N. & Aminudin, N. (2014). Inhibitory effect on in vitro LDL oxidation and HMG Co-A reductase activity of the liquid-liquid partitioned fractions of *Hericium erinaceus* (Bull.) Persoon (lion's mane mushroom). *Biomed. Res. Int*, 2014,828149. doi: 10.1155/2014/828149
76. Rajasekaran, S., Sivagnanam, K. & Subramanian, S. (2005). Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. *Pharmacol Rep*, 57(1), 90–96. doi: 10.1016/j.jacme.2014.01.005
77. Roger, V. L., Go, A. S., Lloyd, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., Lisabeth, L. D., Makuc, D. M., Marcus, G. M., Marelli, A., Matchar, D. B., Moy, C. S., Mozaffarian, D., Mussolino, M. E., Nichol, G., Paynter, N. P., Soliman, E. Z., Sorlie, P. D., Sotoodehnia, N., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D. & Turner, M. B. (2012). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. *Circulation*, 125(1),e2-e220. doi: 10.1161/CIR.0b013e31823ac046
78. Rupcic, Z., Rascher, M., Kanaki, S., Köster, R. W., Stadler, M. & Wittstein, K. (2018). Two New Cyathane Diterpenoids from Mycelial Cultures of the Medicinal Mushroom *Hericium erinaceus* and the Rare Species, *Hericium flagellum*. *Int. J. Mol. Sci*, 19, 740. <https://doi.org/10.3390/ijms19030740>
79. Ryu, S. H., Hong, S. M., Khan, Z., Lee, S. K., Vishwanath, M., Turk, A., Yeon, S. W., Jo, Y. H., Lee, D. H. & Lee, J. K. (2021). Neurotrophic isoindolinones from the fruiting bodies of *Hericium erinaceus*. *Bioorg. Med. Chem. Lett.* 31, 127714. doi: 10.1016/j.bmcl.2020.127714
80. Ryu, S., Kim, H. G., Kim, J. Y., Kim, S. Y. & Cho, K. O. (2018). *Hericium erinaceus* extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain. *J. Med. Food*, 21,174–180. doi: 10.1089/jmf.2017.4006
81. Schildkraut, J. J. (2006). The catecholamine hypothesis of affective disorders: A review of supporting evidence. *Am. J. Psychiatry*, 112, 509-522. doi: 10.1176/ajp.122.5.509
82. Sheu, S. C., Lyu, Y., Lee, M. S. & Cheng, J. H. (2013). Immunomodulatory effects of polysaccharides isolated from *Hericium erinaceus* on dendritic cells. *Process Biochem.* 48(9): 1402-8. doi: 10.1016/j.procbio.2013.06.012
83. Shih, S. C., Tseng, K. W., Lin, S. C., Kao, C. R., Chou, S. Y., Wang, H. Y., Chang, W. H., Chu, C. H., Wang, T. E. & Chien, C. L. (2005). Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer. *World J. Gastroenterol*, 11(1), 136-141. doi: 10.3748/wjg.v11.i1.136
84. Shin, M. H., Kim, J., Lim, S. A., Kim, J., Kim, S. J. & Lee, K. M. (2020). NK Cell-Based Immunotherapies in Cancer. *Immune Netw.* 20(2):e14. doi: 10.4110/in.2020.20.e14
85. Sokol, S., Golak-Siwulska, I., Sobieralski, K., Siwulski, M. & Gorka, K. (2015). Biology, cultivation, and medicinal functions of the mushroom *Hericium erinaceum*. *Acta Mycologica*,50(2), 60-594. doi: 10.5586/am.1069.0
86. Thongbai, B., Rapior, S., Hyde, K. D., Wittstein, K. & Stadler, M. (2015). *Hericium erinaceus*, an amazing medicinal mushroom. *Mycological Progress*, 14(91), 1-23. doi: 10.1007/s11557-015-1105-4
87. Tripodi, F., Falletta, E., Leri, M., Angeloni, C., Beghelli, D., Giusti, L., Milanese, R., Sampaio-Marques, B., Ludovico, P., Goppa, L., Rossi, P., Savino, E., Bucciantini, M. & Coccetti, P. (2022). Anti-Aging and Neuroprotective Properties of *Grifola frondosa* and *Hericium erinaceus* Extracts. *Nutrients*. 14(20):4368. doi: 10.3390/nu14204368
88. Tzeng, T. T., Chen, C. C., Lee, L. Y., Chen, W. P., Lu, C. K., Shen, C. C., Ying, H. F. C, Chen, C. C. & Shiao, Y. J. (2016). Erinacine A-enriched *Hericium erinaceus* mycelium ameliorates Alzheimer's disease-related pathologies in APP^{swe}/PS1^{dE9} transgenic mice. *J. Biomed. Sci*, 23(1), 49. doi: 10.1186/s12929-016-0266-z
89. Uffelmann, C. N., Chan, N. I., Davis, E. M., Wang, Y., McGowan, B. S. & Campbell, W. W. (2023). An Assessment of Mushroom Consumption on Cardiometabolic Disease Risk Factors and Morbidities in Humans: A Systematic Review. *Nutrients*. 15(5):1079. doi:10.3390/nu15051079
90. Wang, J. C., Hu, S. H., Wang, J. T., Chen, K. S. & Chia, Y. C. (2005). Hypoglycemic effect of extract of *Hericium erinaceus*. *J. Sci. Food Agric*, 85, 641–646. doi: 10.1002/jsfa.1928
91. Wang, L. Y., Huang, C. S., Chen, Y. H., Chen, C. C., Chen, C. C. & Chuang, C. H. (2019). Anti-Inflammatory Effect of Erinacine C on NO Production through Down-Regulation of NF- κ B and Activation of Nrf2-Mediated HO-1 in BV2 Microglial Cells Treated with LPS. *Molecules*, 24(18): 3317. doi:10.3390/molecules24183317
92. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*, 27 (5),1047–1053. doi: 10.2337/diacare.27.5.1047

93. Wong, K. H., Vikineswary, S., Abdullah, N., Naidu, M. & Keynes, R. (2007). Activity of aqueous extracts of lion's mane mushroom *Hericiium erinaceus* (Bull Fr) Pers (Aphyllorphoromycetideae) on the neural cell line NG108-15. *Int. J. Med. Mushrooms*, 9, 57–65. doi: 10.3390/antiox8080261
94. Wu, S. H., Kirk, P. M., Redhead, S. A., Stalpers, J. A., Dai, Y. C., Norvell, L. L., Yang, Z. L., Ryvarden, L., Su, C. H., Li, Y. U., Zhuang, W. Y., Yao, Y. J., Chen, C. J., Chen, L. C., Yu, Z. H. & Wang, X. C. (2012). Resolution of the nomenclature for niu-chang-chih (*Taiwanofungus camphoratus*), an important medicinal polypore. *Taxon*, 61 (6),1305–1310. doi: 10.1002/tax.616011
95. Wu, T. & Xu, B. J. (2015). Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. *Int. J. Med. Mushrooms*; 17: 129-40. doi: 10.1615/intjmedmushrooms.v17.i2.40
96. Xie, X., Ren, K. & Zhou, Z. (2022). The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. *BMC Gastroenterol.* 22, 58. <https://doi.org/10.1186/s12876-022-02130-2>
97. Yang, H., Hwang, I. & Kim, S. (2013). *Lentinus edodes* promotes fat removal in hypercholesterolemic mice. *Exp. Ther. Med.* 6(6), 1409–1413. <http://dx.doi.org/10.1155/2019/3030967>
98. Yim, M. H., Shin, J. W., Son, J. Y., Oh, S. M., Han, S. H., Cho, J. H., Cho, C. K., Yoo, H. S., Lee, Y. W. & Son, C. G. (2007). Soluble components of *Hericiium erinaceum* induce NK cell activation via production of interleukin-12 in mice splenocytes. *Acta Pharmacol. Sin*, 28(6), 901–907. doi: 10.1111/j.1745-7254.2007.00577.x
99. Yoshida, H. & Kisugi, R. (2010). Mechanisms of LDL oxidation. *Clinica Chimica Acta*, 411(23-24), 1875–1882. <https://doi.org/10.1016/j.bbacia.2017.07.002>
100. Zhang, Y., Liu, L., Bao, L., Yang, Y., Ma, K. & Liu, H. (2018). Three new cyathane diterpenes with neurotrophic activity from the liquid cultures of *Hericiium erinaceus*. *J Antibiot (Tokyo)*. 71(9):818-821. doi:10.1038/s41429-018-0065-8
101. Zhang, Y., Yang, S., Wang, A., Sun, Z., Zhuo, Y. & Xu, Y. (2015). Protective effect of ethanol extracts of *Hericiium erinaceus* on alloxan-induced diabetic neuropathic pain in rats. *Evid Based Complement Altern Med* 2015. 595480. <https://doi.org/10.1155/2015/595480>
102. Zhang, Z., Lv, G., Pan, H., Pandey, A., He, W. & Fan, L. (2012). Antioxidant and hepatoprotective potential of endo-polysaccharides from *Hericiium erinaceus* grown on tofu whey. *Int. J. Biol. Macromol*, 51(5),1140–1146. doi: 10.1016/j.ijbiomac.2012.09.002
103. Zhao, S., Gao, Q., Rong, C., Wang, S., Zhao, Z., Liu, Y. & Xu, J. (2020). Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products. *J. Fungi (Basel)*. 6(4):269. doi: 10.3390/jof6040269